Skip to main content
Premium Trial:

Request an Annual Quote

Great Basin Receives 510(k) Clearance for C. difficile MDx Test

NEW YORK (GenomeWeb News) – Great Basin today announced it has received 510(k) clearance from the US Food and Drug Administration for its first molecular diagnostic test for Clostridium difficile.

The test is based on a technology that uses an integrated disposable cartridge containing all necessary reagents and runs on a benchtop analyzer. The goal, the Salt Lake City-based firm said, is to deliver assays that can be performed in a CLIA-rated waived or moderately complex laboratory at a lower cost than other molecular diagnostics.

Other firms that offer FDA-cleared molecular tests for C. difficile include Meridian Bioscience, Cepheid, and Gen-Probe through its Prodesse acquisition.

"Workflow matters, especially when diagnosing a difficult-to-treat and time-critical infection like C. diff," Great Basin President and CEO Ryan Ashton said in a statement. "The FDA's clearance of our C. diff assay will give healthcare providers access to a molecular test that improves workflow while providing answers at a cost that makes sense to the hospital."

He added that this year the company intends to augments its menu offering and to initiate clinical trials for a broad panel sepsis assay and a fungal pathogen assay.

Great Basin filed its FDA submission for the C. difficile in November.

The company said it also is launching its C. difficile test as a CE-IVD product in Europe and has begun marketing it in the European Union through local distributors.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.